Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Olema Pharmaceuticals, Inc. (OLMA : NSDQ)

• Company Description    Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California. Number of Employees: 131

• Price / Volume Information    Yesterday's Closing Price: $13.68 Daily Weekly Monthly 20 Day Moving Average: 1,042,194 shares Shares Outstanding: 87.35 (millions) Market Capitalization: $1,194.91 (millions) Beta: 2.05 52 Week High: $36.26 52 Week Low: $3.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.88% -15.23% 12 Week -43.91% -48.15% Year To Date -45.28% -48.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 780 Brannan Street - San Francisco,CA 94103 USA ph: 415-651-3316 fax: - ir@olema.com http://www.olema.com

• General Corporate Information    Officers Sean Bohen - President and Chief Executive Officer Sasha Austin - Vice President; Finance and Controller Ian Clark - Director Cynthia Butitta - Director Cyrus L. Harmon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68062P106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 87.35 Most Recent Split Date: (:1) Beta: 2.05 Market Capitalization: $1,194.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -44.44% vs. Previous Quarter: -4.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -46.00 12/31/25 - -42.95 09/30/25 - -41.56 ROA 03/31/26 - -41.22 12/31/25 - -38.78 09/30/25 - -37.65 Current Ratio 03/31/26 - 10.88 12/31/25 - 9.95 09/30/25 - 8.03 Quick Ratio 03/31/26 - 10.88 12/31/25 - 9.95 09/30/25 - 8.03 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 5.50 12/31/25 - 5.88 09/30/25 - 4.48 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.62 12/31/25 - 0.62 09/30/25 - 0.97

Powered by Zacks Investment Research ©